Sir,

A 20-year-old Caucasian woman with no significant past medical history was referred to the nephrology clinic for new-onset edema of the lower extremities and four positive proteinuria on dipstick. Her serum creatinine was 2.7 mg/dl with an estimated glomerular filtration rate (eGFR) of 24 ml/min/1.73 m^2^. The 24-h urine protein was measured at 18.8 g. A thorough biologic and immunologic work-up was negative. The renal biopsy revealed type III membranoproliferative glomerulonephritis (MPGN). The patient was started on high dose intravenous methylprednisolone (500 mg/day for 3 days) followed by oral methylprednisolone (16 mg/day) and mycophenolate mofetil (MMF) (500 mg twice a day). Six weeks later, serum creatinine improved to 1.7 mg/dl and proteinuria decreased to 5.5 g/24 h. The MMF dose was subsequently increased to 500 mg three times a day. At 6 months, her serum creatinine continued to improve to 1.4 mg/dl with a proteinuria of 2.8 g/24 h. She has continued this regimen associated with an angiotensin converting enzyme inhibitor for the past 24 months with no major complications while her kidney function remains stable with an eGFR of 50 ml/ min/1.73 m^2^ and a proteinuria persistently \<3 g/24 h.

Idiopathic MPGN (IMPGN) is a rare disorder and accounts for only 6.4 to 7.3% of all primary glomerular diseases \[[@R1]\]. It is generally regarded as a progressive disease. Compared to secondary forms of MPGN, the renal outcome in these patients is usually poor, with a 10-year renal survival of 32--40% and only 5--7.6% of patients achieving at least partial remission \[[@R1]\]. Up to 50 to 60% of untreated patients will progress to end-stage renal disease within 10-- 15 years; spontaneous improvement occurs in \<10% of cases \[[@R2]\].

While steroids have frequently been used for the treatment of IMPGN, it should be noted that studies evaluating the role of steroids have often been conducted in children; there has been no systematic evaluation of steroid therapy for IMPGN in adults. Indeed, retrospective studies have not shown any clear benefit from steroid therapy.

MMF is an antimetabolite agent with potent antiproliferative properties against T cells and B cells, as well as a number of non-lymphoid cell types. It has previously been used in a number of primary glomerular diseases (e.g. lupus nephritis) with promising results in reducing proteinuria. Recently, MMF has been introduced as a potential therapeutic option for MPGN. Some studies reported that proteinuria significantly diminished with therapy while no change was observed in untreated control patients \[[@R1]\]. Other reports have also suggested the benefit of treatment with MMF (Table [1](#T1){ref-type="table"}). Our observations, coupled with previous reports, provide evidence that MMF may have a role in the treatment of IMPGN. Further randomized studies with adequate sample size and extended follow-up are clearly needed to confirm these observations and to evaluate the long-term safety of this management strategy.

###### 

Summary of studies on the role of MMF^a^ in the treatment of MPGN^b^

  Study                        Number of patients   Steroid therapy   Pre-MMF creatinine clearance (ml/min)^c^   Post-MMF creatinine clearance (ml/min)^c^   Pre-MMF proteinuria (g/24 h)^d^   Post-MMF proteinuria (g/24 h)^d^   Comment
  ---------------------------- -------------------- ----------------- ------------------------------------------ ------------------------------------------- --------------------------------- ---------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------
  Jones *et al*. \[[@R1]\]     5                    \+                105.3                                      106.4                                       5.08                              1.96                               Significant reduction in proteinuria over 18 months (creatinine clearance significantly reduced in the control group while no change in proteinuria)
  Levin \[[@R3]\]              1                    \+                56                                         98--106                                     16                                \< 0.1                             Excellent response at 12 months both for creatinine clearance and for proteinuria
  Segarra *et al*. \[[@R4]\]   15                   --                54.5                                       52.3                                        6.05                              3.1                                Although mean proteinuria for the 'whole group' significantly decreased at 12 months, it had remained unchanged in 53% of the patients
  Choi *et al*. \[[@R5]\]      1                    --                31^e^                                      31^e^                                       4.9^f^                            3.9^f^                             Serum creatinine initially decreased but returned to baseline after reduction in MMF dose
  Present case                 1                    \+                24                                         50                                          18.8                              \< 3                               At 24 months, improvement in creatinine clearance and major reduction in proteinuria

^a^MMF: mycophenolate mofetil.

^b^MPGN: membranoproliferstive glomerulonephritis.

^c^For the studies including more than one patient, this number reflects the 'mean' creatinine clearance.

^d^For the studies including more than one patient, this number reflects the 'mean' proteinuria.

^e^The study does not mention creatinine clearance. The current creatinine clearance has been calculated according to the MDRD formula based on the information provided in the paper.

^f^This number reflects the random urine protein/urine creatinine ratio.
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